Moneycontrol PRO
you are here: HomeNewsBusiness

Global supply chain to witness shift, low imports from China will benefit: Raymond

It is also looking at long-term funding and alternate working capital availability to manage liquidity as business restarts with gradual easing of lockdown.

June 30, 2020 / 02:59 PM IST
  • bselive
  • nselive
Todays L/H

Homegrown textiles and apparels major Raymond expects to reap the benefits of likely low imports from China in view of the COVID-19 pandemic, the company said in a statement on Tuesday.

It is also looking at long-term funding and alternate working capital availability to manage liquidity as business restarts with gradual easing of lockdown.

Disclosing its current status of operations post lockdown, the company said commodity prices have softened due to the pandemic. This would lower the input costs and support the overall profitability this fiscal.

“Easing of commodity prices such as of cotton and wool are likely to benefit the company going forward along with softened oil prices,” it said.

Referring to expected low imports from China in the present scenario, Raymond said it "is expected to reap benefits of low imports from China as global supply chain will witness a shift. The company expects the exports to resume soon with opening up of global economies."

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Raymond also said it has undertaken cost rationalisation and control measures related to “manpower, sales and marketing, rentals and others to minimise the impact on business".

On resumption of business, Raymond said gradual reopening began from lockdown 3.0 onwards, wherein the government permitted sale of certain nonessential items in specified geographies.

Currently, 1,332 stores have reopened adhering to all COVID-19 related guidelines for employees and customers, it added.

Commenting on its liquidity position, Raymond said it is taking all requisite measures to manage liquidity that includes cost reduction, fund management and focus on collections.

The company is looking at all available options that include long term funding and alternate working capital availability to manage liquidity in the current situation, it added.

The company is in the process of taking steps to issue non convertible debentures (NCDs) that would support the rebalancing of its debt mix favouring long-term debt, it said adding that in June quarter of 2020-21, the company has raised Rs 145 crore through NCDs at market benchmarked rates.

"In line with the prevailing market conditions and unprecedented challenges, the company has undertaken the process of cost rationalisation & various cost control measures related to manpower, sales and marketing, rentals and others to minimise the impact on business," the company said.

On operations of manufacturing plants, Raymond said its suiting and shirting fabric manufacturing units continue to remain shut due to subdued demand.

“Production planning and reopening of plants in a phased manner is under evaluation,” it said.

The company's garmenting facilities and tools, hardware and auto components segments have partially resumed operations, it added.

On Monday, Raymond declared its quarterly and annual results ended March 31, 2020.

Raymond reported a consolidated net loss of Rs 69.10 crore for January-March 2020 impacted by COVID-19 and the lockdown.

Revenue from operations was down 29.30 percent to Rs 1,278.65 crore during the quarter under review as against Rs 1,808.71 crore in the corresponding period of the previous fiscal.

Follow our full coverage of the coronavirus pandemic here.

first published: Jun 30, 2020 02:35 pm